Literature DB >> 29130931

Confounding role of tumor necrosis factor in cryopyrin-associated periodic syndromes.

Balaji Banoth, Fayyaz S Sutterwala.   

Abstract

The NLRP3 inflammasome is a critical component of the innate immune system and can be activated in response to microbial and endogenous danger signals. Activation of the NLRP3 inflammasome results in caspase-1-dependent secretion of the proinflammatory cytokines IL-1β and IL-18. Gain-of-function missense mutations in NLRP3 result in a group of autoinflammatory diseases collectively known as the cryopyrin-associated periodic syndromes (CAPS). CAPS patients have traditionally been successfully treated with therapeutics targeting the IL-1 pathway; however, there are a number of identified CAPS patients who show only a partial response to IL-1 blockade. In this issue of the JCI, McGeough et al. demonstrated that TNF-α, in addition to IL-1β, plays an important role in promoting NLRP3 inflammasomopathies.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29130931      PMCID: PMC5707140          DOI: 10.1172/JCI98322

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

Review 1.  Sensing damage by the NLRP3 inflammasome.

Authors:  Jaklien C Leemans; Suzanne L Cassel; Fayyaz S Sutterwala
Journal:  Immunol Rev       Date:  2011-09       Impact factor: 12.988

Review 2.  Mechanism of NLRP3 inflammasome activation.

Authors:  Fayyaz S Sutterwala; Stefanie Haasken; Suzanne L Cassel
Journal:  Ann N Y Acad Sci       Date:  2014-05-19       Impact factor: 5.691

3.  TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies.

Authors:  Matthew D McGeough; Alexander Wree; Maria E Inzaugarat; Ariela Haimovich; Casey D Johnson; Carla A Peña; Raphaela Goldbach-Mansky; Lori Broderick; Ariel E Feldstein; Hal M Hoffman
Journal:  J Clin Invest       Date:  2017-11-13       Impact factor: 14.808

4.  Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling.

Authors:  Nobuhiko Kayagaki; Irma B Stowe; Bettina L Lee; Karen O'Rourke; Keith Anderson; Søren Warming; Trinna Cuellar; Benjamin Haley; Merone Roose-Girma; Qui T Phung; Peter S Liu; Jennie R Lill; Hong Li; Jiansheng Wu; Sarah Kummerfeld; Juan Zhang; Wyne P Lee; Scott J Snipas; Guy S Salvesen; Lucy X Morris; Linda Fitzgerald; Yafei Zhang; Edward M Bertram; Christopher C Goodnow; Vishva M Dixit
Journal:  Nature       Date:  2015-09-16       Impact factor: 49.962

5.  Use of canakinumab in the cryopyrin-associated periodic syndrome.

Authors:  Helen J Lachmann; Isabelle Kone-Paut; Jasmin B Kuemmerle-Deschner; Kieron S Leslie; Eric Hachulla; Pierre Quartier; Xavier Gitton; Albert Widmer; Neha Patel; Philip N Hawkins
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

6.  Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.

Authors:  Mark C Genovese; Stanley Cohen; Larry Moreland; Deborah Lium; Sean Robbins; Richard Newmark; Pirow Bekker
Journal:  Arthritis Rheum       Date:  2004-05

7.  Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity.

Authors:  Susannah D Brydges; James L Mueller; Matthew D McGeough; Carla A Pena; Amirhossein Misaghi; Chhavi Gandhi; Chris D Putnam; David L Boyle; Gary S Firestein; Anthony A Horner; Pejman Soroosh; Wendy T Watford; John J O'Shea; Daniel L Kastner; Hal M Hoffman
Journal:  Immunity       Date:  2009-06-04       Impact factor: 31.745

8.  A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses.

Authors:  Guangxun Meng; Fuping Zhang; Ivan Fuss; Atsushi Kitani; Warren Strober
Journal:  Immunity       Date:  2009-06-04       Impact factor: 31.745

9.  Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist.

Authors:  Hal M Hoffman; Sanna Rosengren; David L Boyle; Jae Y Cho; Jyothi Nayar; James L Mueller; Justin P Anderson; Alan A Wanderer; Gary S Firestein
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

10.  Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.

Authors:  Raphaela Goldbach-Mansky; Natalie J Dailey; Scott W Canna; Ana Gelabert; Janet Jones; Benjamin I Rubin; H Jeffrey Kim; Carmen Brewer; Christopher Zalewski; Edythe Wiggs; Suvimol Hill; Maria L Turner; Barbara I Karp; Ivona Aksentijevich; Frank Pucino; Scott R Penzak; Margje H Haverkamp; Leonard Stein; Barbara S Adams; Terry L Moore; Robert C Fuhlbrigge; Bracha Shaham; James N Jarvis; Kathleen O'Neil; Richard K Vehe; Laurie O Beitz; Gregory Gardner; William P Hannan; Robert W Warren; William Horn; Joe L Cole; Scott M Paul; Philip N Hawkins; Tuyet Hang Pham; Christopher Snyder; Robert A Wesley; Steven C Hoffmann; Steven M Holland; John A Butman; Daniel L Kastner
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

View more
  3 in total

1.  REV-ERBα integrates colon clock with experimental colitis through regulation of NF-κB/NLRP3 axis.

Authors:  Shuai Wang; Yanke Lin; Xue Yuan; Feng Li; Lianxia Guo; Baojian Wu
Journal:  Nat Commun       Date:  2018-10-12       Impact factor: 14.919

2.  The Efficacy of Anti-Tumor Necrosis Factor Therapy in Cryopyrin-Associated Periodic Syndromes: A Report of Two Cases.

Authors:  Fatemeh Tahghighi; Mahdieh Vahedi; Nima Parvaneh; Mohammad Shahrooei; Vahid Ziaee
Journal:  Case Rep Genet       Date:  2022-03-03

3.  Neuroprotective Effects of Qingnao Dripping Pills Against Cerebral Ischemia via Inhibiting NLRP3 Inflammasome Signaling Pathway: In Vivo and In Vitro.

Authors:  Chen Fu; Xinyang Zhang; Zixiu Zeng; Yang Tian; Xianglan Jin; Fengli Wang; Zhenmin Xu; Baoxin Chen; Hong Zheng; Xuemei Liu
Journal:  Front Pharmacol       Date:  2020-02-20       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.